GUFIC BIOSCIENCES
|
|
BOM : 509079     NSE : GUFICBIO     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Dec 05,2024 |
Price(EOD): ₹ 446.50
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 4,478.40 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GUFIC BIOSCIENCES | 7.1% | 0.8% | 33.7% |
SUN PHARMACEUTICAL INDUSTRIES | 3.7% | -3.2% | 46.6% |
CIPLA | 0.6% | -3.7% | 26.7% |
DR REDDYS LABORATORIES | 1.9% | -3.4% | 5.8% |
ZYDUS LIFESCIENCES | 2.3% | -3.4% | 54% |
DIVIS LABORATORIES | 5.1% | 6.1% | 64% |
MANKIND PHARMA | 1.3% | -3.5% | 35.8% |
TORRENT PHARMACEUTICALS | 4.6% | 4.4% | 58% |
LUPIN | 5.1% | -4.4% | 62.5% |
FUNDAMENTAL ANALYSIS OF GUFIC BIOSCIENCES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GUFIC BIOSCIENCES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
52.71
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 84.94 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 8.41
P/B Calculated based on Book Value of Rs 532.56 Cr
[Latest Year - Mar2024 - Standalone Results ] 5.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
171% 237% 219% |
SHARE PRICE MOMENTUM OF GUFIC BIOSCIENCES
GUFIC BIOSCIENCES vs SENSEX
DEBT OF GUFIC BIOSCIENCES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.6 0.9 0.23 0.58 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GUFIC BIOSCIENCES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GUFIC BIOSCIENCES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.67% 7.94% 4.1% 4.4% |
-4.98% -1.89% -5.44% -6.18% |
QtrlyTrend |
0 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
GUFIC BIOSCIENCES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 4.1% | 1% | 46.7% |
S&P BSE SMALL CAP | 3.5% | 2% | 40.5% |
S&P BSE MIDSMALLCAP | 3.4% | 3% | 40.6% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
You may also like the below Video Courses
FAQ about GUFIC BIOSCIENCES
Is GUFIC BIOSCIENCES good for long term investment?
As on Dec 05,2024, the Fundamentals of GUFIC BIOSCIENCES look Strong and hence it may be good for long term investment! See Financial Performance of GUFIC BIOSCIENCES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GUFIC BIOSCIENCES UnderValued or OverValued?
As on Dec 05,2024, GUFIC BIOSCIENCES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GUFIC BIOSCIENCES ?
As on Dec 05,2024, the Intrinsic Value of GUFIC BIOSCIENCES is Rs. 139.76 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 165.04
Fair Value [Median EV / Sales Model] : Rs. 132.53
Fair Value [Median Price / Sales Model] : Rs. 139.76
Estimated Median Fair Value of GUFIC BIOSCIENCES : Rs. 139.76
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.